TableĀ 1

Biologic and oral DMARDs approved for the treatment of patients with rheumatoid arthritis

AgentMechanism of actionLocationRegimen
EtanerceptTNFiUSA and EuropeMonotherapy
AdalimumabTNFiUSA and EuropeMonotherapy
InfliximabTNFiUSA and EuropeIn combination with MTX only
Certolizumab pegolTNFiUSA and EuropeMonotherapy
GolimumabTNFiUSA and EuropeIn combination with MTX only
TocilizumabIL-6 receptor inhibitorUSA and EuropeMonotherapy
AnakinraIL-1 receptor inhibitorUSAMonotherapy
AbataceptInhibitor of T-cell activation (costimulation modulator)USAMonotherapy
RituximabAnti-CD20USA and EuropeIn combination with a DMARD only
TofacitinibJAK inhibitorUSAMonotherapy
  • DMARD, disease-modifying antirheumatic drug; IL, interleukin; JAK, janus kinase; MTX, methotrexate; TNFi, tumour necrosis factor inhibitor.